OREANDA-NEWS. Acerus Pharmaceuticals Corporation (TSX:ASP) today served a notice of motion to strike the statement of claim filed in the Ontario Superior Court of Justice by Mr. Eugene Melnyk against the company, as well as its Chairman and President & Chief Executive Officer.

Acerus is proceeding with a motion to strike on the grounds that the claim discloses no reasonable cause of action and that the claim is frivolous, scandalous and/or vexatious, and represents an abuse of process of the court. The company maintains its position regarding the appropriate conduct of the business and its management, and will continue to vigorously defend against all such claims that imply otherwise.

Acerus Pharmaceuticals Corporation is a Canadian pharmaceutical company focused on the development, manufacture, marketing and distribution of innovative, branded products that improve the patient experience.

Acerus markets ESTRACE® in Canada, a product indicated for the symptomatic relief of menopausal symptoms. NATESTO™, a product utilizing an Acerus licensed nasal gel technology, is the first and only testosterone nasal gel approved in Canada, and available in the United States for replacement therapy in adult males diagnosed with hypogonadism. GYNOFLOR™, a product licensed to Acerus in Canada by Medinova AG and approved in 39 countries worldwide, is an ultra-low dose vaginal estrogen therapy with the addition of lactobacillus, for the treatment of atrophic vaginitis, certain vaginal infections and/or to restore a healthy vaginal environment. TEFINA™, a ‘use as required’ nasal testosterone gel, is an Acerus drug development candidate aimed at addressing a significant unmet need for women with female sexual dysfunction.